News

Abbott’s Infinity Deep Brain Stimulator now allows for performance of MRI on patients with Parkinson or essential tremor with the system implanted.

The vice president of US Medical Affairs in Neurology & Immunology at EMD Serono discussed the potential for the oral multiple sclerosis therapy.

African-American patients with MS on fingolimod were 50.2% more likely to remain true to their treatment regimen than those treated with injectable disease-modifying therapies.

The EMD Serono therapy’s resubmission was accepted after a 2011 CRL, with the new NDA supported by the findings of a 5-study clinical development program.

A third-party manufacturing issue has delayed a phase I/IIa study for Sarepta Therapeutics.

This is the first large late-stage clinical trial to further support the amyloid hypothesis.

The SPRINT MIND trial found a statistically significant lower rate of new cases of mild cognitive impairment in the intensive treatment group.

The psychiatry and pharmacology professor spoke about the results from the first clinical trial that showed that a cannabinoid can decrease agitation in Alzheimer disease.

Efficacy was demonstrated in this patient population at the primary endpoint of 6 weeks, especially in those with more severe baseline NPI-NH-PS.

Data from an interim analysis of the lumateperone large phase III clinical trial for agitation in subjects with dementia is expected by the end of 2018.

These guidelines will provide primary clinicians and the specialist community an important new tool to more accurately diagnose patients.

The FDA has granted a Breakthrough Device Designation to the Elecsys beta-Amyloid (1-42) and Elecsys Phospho-Tau (181P) cerebrospinal fluid assays, which can be used in the diagnosis of Alzheimer disease.

Neurological findings tell us why decision-making functions of the brain can be altered based on certain life experiences.

TNX-102 SL’s impact on sleep disturbance highlights a mechanism of action that could result in positive effects on agitation in AD.

The addition of ZX008 to background stiripentol significantly reduced the number of convulsive seizures experienced by children and young adults with Dravet syndrome.

After success in migraine treatment, CGRP has now shown a positive effect on acute cluster headache in a randomized clinical trial.

The FDA has accepted a supplemental new drug application for sodium oxybate as a treatment for cataplexy and excessive daytime sleepiness in children with narcolepsy.

Given that suicide is increasing as a public health concern, better identification of warning signs could assist in directing preventative strategies to the right people.

The anti-amyloid protofibril antibody achieved statistical significance in its key efficacy endpoints after 18 months.

Which sports-related migraine is associated with longer recovery time, as well as cognitive, neurobehavioral, and somatic symptoms? Test your skills in this quiz.

The autologous stem cell therapy is currently in a phase III trial.

Phase III results have shown galcanezumab is efficacious for multiple headache conditions.

The anti-CGRP treatment continues reducing migraine days a year after patients received infusions.

Rimegepant significantly reduced pain and the most bothersome symptom while showing an "excellent" safety profile for patients with acute migraine attacks.

The intravenous quarterly CGRP inhibitor eptinezumab significantly reduced monthly migraine days compared with placebo for patients with chronic migraine.

We're trying to make our stress tests more realistic.

A retrospective analysis of a dose-ranging trial found that those who were administered 100-mg daily riluzole, in comparison with placebo, spend a longer period of time in stage 4 of ALS.

The FDA had accepted a new drug application for APL-130277, a sublingual film version of apomorphine, as a treatment for OFF episodes in patients with Parkinson disease.